Newsroom

Sera announced publication of a new subgroup analysis from the PRIME randomized controlled trial.

Sera today announced that Mark Capone will join its Board of Directors, effective July 1, 2026.

Sera announced its participation in a multi-institutional research program that was awarded up to $10.4 million by the Advanced Research Projects Agency for Health (ARPA-H) to develop a novel point-of-care diagnostic test designed to improve the safety of labor and delivery.

Sera today acknowledged recent legislative action in Illinois aimed at expanding access to evidence-based approaches for identifying and managing the risk of preterm birth among pregnant individuals. 

Sera announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company’s upcoming Annual Meeting of Shareholders.

Sera announced financial results for the first quarter ended March 31, 2026.

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.

Sera announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study were accepted for publication in a peer-reviewed  journal.

Sera announced financial results for the third quarter of 2025 ended September 30, 2025.